China's Vibrant Therapeutics has raised tens of millions USD in Series A funding led by Trinity Innovation Fund and HongShan to advance its T-cell engager (TCE) platform for solid tumours. Founded in 2019, the Guangzhou-based biotech combines computational design and wet-lab validation to develop bispecific antibodies (BsAbs) targeting tumour microenvironment (TME) antigens. The funding will support global clinical trials for lead candidates and expansion of its AI-driven molecular engineering platform.

An Apricot Capital partner highlighted Vibrant's potential to overcome current limitations of TCEs in solid tumours. The company's leadership team includes veterans from Schering-Plough, Merck and GenScript with 20+ years of biologics experience. Vibrant aims to file investigational new drug (IND) applications for its first programs in 2026, targeting cancers with high unmet needs through its proprietary multispecific antibody design capabilities.

PharmCube's NextBiopharm® database list five assets in Vibrant's pipeline, all pre-clinical candidates in oncology. Click here to request a free trial for NextBiopharm®.